Developer docs
API playgroundTry for free, no card

Search company profiles

C2N Diagnostics

Full company profile

uuid00004sj

Namestring
C2N Diagnostics
Legal namestring
C₂N Diagnostics, LLC
Websiteurl
c2n.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

C2N Diagnostics is a St. Louis-based specialty diagnostics company developing blood-based tests for Alzheimer's disease and related neurodegenerative conditions. Founded in 2007 by Washington University neurologists Dr. David Holtzman and Dr. Randall Bateman, the company operates a CAP-accredited, CLIA-certified, ISO 13485:2016-compliant laboratory that performs tests using proprietary high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies licensed from the WashU Bateman Lab. Its clinical product portfolio includes PrecivityAD2™ (for patients aged 50+), PrecivityAD® (for patients aged 55+), and Precivity-ApoE™, with the research pipeline adding C2N eMTBR-tau243 and C2N %p-tau MAA assays focused on tau tangle pathology.

The company generates revenue primarily through per-test fees charged to healthcare professionals who order Precivity™ tests on behalf of patients; PrecivityAD is priced at $1,250 per test. Distribution extends across all 50 US states (enabled by the November 2025 NY State CLEP permit), Canada, the UK (via 2025 MHRA certification), and 18+ international markets through partnerships with Mayo Clinic Laboratories, Unilabs (75+ countries), and regional distributors across Asia-Pacific, Latin America, and the Middle East. A secondary revenue stream comes from bioanalytical services supporting pharmaceutical and academic clients, including Eisai's Alzheimer's programs and Phase 3 trials (Evoke/Evoke+) using C2N's eMTBR-tau243 assay for clinical trial recruitment and treatment monitoring.

Customer segments span healthcare providers (primary care, neurologists, memory care specialists), biopharmaceutical companies (clinical trial screening and treatment monitoring), and academic researchers (with over 200 published studies using C2N assays). The company is venture-backed with roughly $100M+ raised cumulatively across nine rounds from GHR Foundation, Samsung entities, ADDF, Eisai, and the Michael J. Fox Foundation, and is tripling its operational footprint via an 82,451-square-foot headquarters under construction at the Cortex Innovation District in St. Louis. C2N also disclosed a cybersecurity incident in April 2026 affecting employee email communications.

Short descriptiontext

C2N Diagnostics is a St. Louis specialty diagnostics company developing proprietary blood-based tests for Alzheimer's disease using high-resolution mass spectrometry, serving healthcare providers, biopharmaceutical trial sponsors, and academic researchers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Alzheimer's disease diagnostics, blood-based biomarker testing, mass spectrometry diagnostics, neurodegenerative disease assays, clinical laboratory services
Industry4 codes
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Neurological Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Laboratory Testing Services
TypeOne Time License
Description

C2N performs its Precivity™ blood tests in its CAP-accredited, CLIA-certified, ISO 13485:2016 compliant laboratory in St. Louis, Missouri. Healthcare professionals order tests for patients, and results are returned to inform medical management and treatment decisions. Revenue is generated per test performed.

c2n.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels10 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1PrecivityAD Test - $1,250 per test
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

The PrecivityAD test costs $1,250. The company offers financial assistance for eligible consumers. Medicare and private insurance coverage was being pursued at time of reporting.

c2n.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1PrecivityAD
Description

Blood test for Alzheimer's disease intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia undergoing evaluation for Alzheimer's disease or dementia

c2n.com
+2 more records
Core offering1 text field

C2N Diagnostics develops and commercializes proprietary blood-based diagnostic tests for Alzheimer's disease and related neurodegenerative conditions using high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology. The core Precivity™ product line includes PrecivityAD®, PrecivityAD2™, and Precivity-ApoE™ clinical diagnostic tests, complemented by research-use-only tau assays (C2N eMTBR-tau243 and C2N %p-tau MAA) and bioanalytical services for pharmaceutical clinical trials. All clinical tests are processed in the company's CAP-accredited, CLIA-certified laboratory in St. Louis, Missouri, with global distribution through laboratory network and regional distribution partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 91% accuracy, 90% sensitivity, 92% specificity versus amyloid PET imaging
+4 more records
Product overview1 text field

C2N Diagnostics offers a portfolio of blood-based diagnostic tests for Alzheimer's disease using proprietary high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies. The core clinical products include PrecivityAD2™ (for patients 50+), PrecivityAD® (for patients 55+), and Precivity-ApoE™. Research-use-only offerings include C2N eMTBR-tau243 plasma assay and C2N %p-tau MAA for tau pathology analysis. The company also provides bioanalytical services for clinical trials and pharmaceutical research partnerships. Tests are performed in the company's CAP-accredited, CLIA-certified, ISO 13485:2016 compliant facility in St. Louis, MO, and distributed globally through laboratory and distribution partnerships.

Product and service7 records
1PrecivityAD2™ Blood Test
CategoryClinical Diagnostics - Alzheimer's Disease
Description

Blood test intended for patients aged 50 and older with signs or symptoms of mild cognitive impairment or dementia undergoing evaluation of Alzheimer's disease or dementia. Uses high-resolution mass spectrometry to detect amyloid plaques in the brain by measuring plasma p-tau217 and Aβ42/Aβ40 ratio. Performed in C2N's CAP-accredited, CLIA-certified laboratory.

2PrecivityAD® Blood Test
CategoryClinical Diagnostics - Alzheimer's Disease
Description

Original blood test intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia undergoing evaluation of Alzheimer's disease or dementia. Uses mass spectrometry to measure amyloid proteins and apolipoprotein E genetic risk factors for Alzheimer's disease.

3Precivity-ApoE™ Blood Test
CategoryClinical Diagnostics - Genetic Risk Assessment
Description

Blood test indicated for adult patients for whom knowledge of apolipoprotein E2, E3, and E4 allele status may be informative for medical management and treatment decisions. Available through healthcare professional orders.

4C2N eMTBR-tau243 Plasma Assay
CategoryResearch Assay - Tau Pathology
Description

Research Use Only plasma assay that selectively detects a specific region of tau (endogenous Microtubule Binding Region) shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer's disease. Used for disease staging, predicting progression, and monitoring treatment efficacy in research and clinical trial settings.

5C2N %p-tau MAA (Multi-Analyte Assay)
CategoryResearch Assay - Tau Pathology
Description

Research Use Only p-tau multi-analyte assay using high-resolution mass spectrometry to precisely quantitate six analytes related to phosphorylated and non-phosphorylated tau forms (%p-tau181, %p-tau205, %p-tau217). Uses ratio of phosphorylated tau divided by non-phosphorylated tau to mitigate confounding factors such as age and medical comorbidities.

6C2N eMTBR-tau243 (CSF) Assay
CategoryResearch Assay - CSF Tau Biomarkers
Description

Cerebrospinal fluid (CSF) assay launched by C2N for detecting eMTBR-tau243 biomarkers, selectively identifying tau fragment regions for Alzheimer's research applications.

7Bioanalytical Services
CategoryBioanalytical / Clinical Trial Services
Description

High-resolution mass spectrometry-based biomarker services for clinical trials, supporting pharmaceutical and biotechnology companies in maximizing quality and efficiency of neurodegeneration treatment trials. Assays have been used in over 200 Alzheimer's disease research studies globally.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-01
Description

Partnership to enable broader access to Precivity® blood tests across Latin America and Caribbean including Argentina, Chile, Colombia, Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-20
Description

Partnership to launch PrecivityAD2 blood test in Hong Kong for early detection of Alzheimer's disease. Codex handles local regulatory compliance, distribution, and patient access.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-11
Description

Partnership to launch PrecivityAD2 blood test in South Korea, making the test accessible to healthcare professionals for detecting amyloid plaques in patients 50 and older with cognitive impairment.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

Distribution partner for PrecivityAD2 test in Singapore and Southeast Asian markets.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

Distribution partner for PrecivityAD2 test in India.

6Medical Link
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

Distribution partner for PrecivityAD2 test in Israel.

biospace.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

Distribution partner for PrecivityAD2 test in Costa Rica and Mexico.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

Distribution partner for PrecivityAD2 test in Philippines.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

International laboratory partner for C2N's Precivity™ diagnostic tests.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

International laboratory partner for C2N's Precivity™ diagnostic tests.

11Mediford
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

Research collaboration partner for Precivity™ Alzheimer's blood test expansion in Japan.

biospace.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-26
Description

Partnership to transform global clinical trial recruitment for Alzheimer's disease using Precivity™ blood tests to identify eligible patients for clinical trials.

13The Michael J. Fox Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-15
Description

Research partnership to uncover new links between Parkinson's disease, Lewy Body Dementia, and Alzheimer's disease using C2N's biomarker tests.

c2n.com
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-08-07
Description

Global partnership to make Precivity™ blood tests available across Unilabs' laboratory network in 75+ countries, advancing brain health diagnostics internationally.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-06-27
Description

C2N's Precivity™ tests offered through Mayo Clinic Laboratories, providing access through one of the most respected laboratory networks in the United States.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Quanterix operates a single-molecule array (Simoa) ultra-sensitive protein detection platform used by researchers and clinical labs for blood-based biomarkers, including neurodegenerative disease assays. Directly comparable to C2N in that it sells biomarker testing services and immunoassay-based kits to pharma and academic researchers pursuing early AD detection and other neurology applications.

TypeDirect peer
Description

ALZpath developed a proprietary p-tau217 antibody and offers a blood-based Alzheimer's diagnostic test as a laboratory-developed test. Directly competes with C2N's PrecivityAD2 by offering an alternative blood-based AD biomarker assay to the same healthcare provider and biopharma customer base.

3Fujirebio (H.U. Group Holdings)
TypeDirect peer
Description

Fujirebio developed the Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio assay, the first FDA-cleared blood test for AD assessment. Directly competes with C2N in clinical blood-based AD diagnostics, with established IVD manufacturing scale and global distribution.

TypeBroad incumbent
Description

Roche has launched Elecsys pTau217 blood-based AD assays as part of its broad diagnostics portfolio. While not specialized in neurology, Roche's massive installed base of immunoassay analyzers in hospital labs represents a significant competitive threat to specialty labs like C2N.

TypeBroad incumbent
Description

Lilly is commercializing Kisunla (donanemab) for early symptomatic AD and is investing in companion diagnostics and blood-based biomarkers. As a vertically integrated pharma developing its own diagnostic strategy, Lilly is both a potential partner and a competitor for C2N's clinical trial and patient testing services.

TypeBroad incumbent
Description

Sysmex developed an automated immunoassay platform for blood-based p-tau217 measurement (HISCL) and is expanding into clinical AD diagnostics in Japan and globally. Comparable to C2N as a blood-based AD test developer, with broader IVD scale but limited single-disease specialization.

7Eisai
TypeBroad incumbent
Description

Eisai is a strategic investor and partner in C2N ($15M partnership) and commercializes Leqembi (lecanemab) for early AD. As both a commercial partner and developer of companion diagnostics, Eisai is highly comparable to C2N's positioning in the AD ecosystem, with broader pharma scale.

TypeBroad incumbent
Description

Biogen developed Aduhelm and is a major AD therapeutics player with extensive investment in biomarker development. Operates in the same AD clinical ecosystem as C2N and is a potential pharma partner or acquirer for AD diagnostic capabilities.

TypeBroad incumbent
Description

AbbVie partnered with C2N on the C2N-8E12 (ABBV-8E12) Phase 1 program for Progressive Supranuclear Palsy. As a large neuroscience-focused pharma with AD/PSP programs, AbbVie is both a current partner and a comparable player in neurodegenerative biomarker-driven drug development.

TypeEmerging player
Description

SomaLogic operates a SomaScan proteomics platform enabling large-scale biomarker discovery across multiple disease areas including neurodegeneration. Comparable to C2N in its use of advanced proteomic technology for biomarker discovery, though C2N is more clinically focused while SomaLogic serves primarily research customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

C2N Diagnostics

Neurological Diagnosticsc2n.com

C2N Diagnostics is a St. Louis specialty diagnostics company developing proprietary blood-based tests for Alzheimer's disease using high-resolution mass spectrometry, serving healthcare providers, biopharmaceutical trial sponsors, and academic researchers globally.

What C2N Diagnostics does

C2N Diagnostics is a St. Louis-based specialty diagnostics company developing blood-based tests for Alzheimer's disease and related neurodegenerative conditions. Founded in 2007 by Washington University neurologists Dr. David Holtzman and Dr. Randall Bateman, the company operates a CAP-accredited, CLIA-certified, ISO 13485:2016-compliant laboratory that performs tests using proprietary high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies licensed from the WashU Bateman Lab. Its clinical product portfolio includes PrecivityAD2™ (for patients aged 50+), PrecivityAD® (for patients aged 55+), and Precivity-ApoE™, with the research pipeline adding C2N eMTBR-tau243 and C2N %p-tau MAA assays focused on tau tangle pathology.

The company generates revenue primarily through per-test fees charged to healthcare professionals who order Precivity™ tests on behalf of patients; PrecivityAD is priced at $1,250 per test. Distribution extends across all 50 US states (enabled by the November 2025 NY State CLEP permit), Canada, the UK (via 2025 MHRA certification), and 18+ international markets through partnerships with Mayo Clinic Laboratories, Unilabs (75+ countries), and regional distributors across Asia-Pacific, Latin America, and the Middle East. A secondary revenue stream comes from bioanalytical services supporting pharmaceutical and academic clients, including Eisai's Alzheimer's programs and Phase 3 trials (Evoke/Evoke+) using C2N's eMTBR-tau243 assay for clinical trial recruitment and treatment monitoring.

Customer segments span healthcare providers (primary care, neurologists, memory care specialists), biopharmaceutical companies (clinical trial screening and treatment monitoring), and academic researchers (with over 200 published studies using C2N assays). The company is venture-backed with roughly $100M+ raised cumulatively across nine rounds from GHR Foundation, Samsung entities, ADDF, Eisai, and the Michael J. Fox Foundation, and is tripling its operational footprint via an 82,451-square-foot headquarters under construction at the Cortex Innovation District in St. Louis. C2N also disclosed a cybersecurity incident in April 2026 affecting employee email communications.

C2N Diagnostics firmographics

Firmographics
Name
C2N Diagnostics
Legal name
C₂N Diagnostics, LLC
Website
https://c2n.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
C2N Diagnostics is a St. Louis specialty diagnostics company developing proprietary blood-based tests for Alzheimer's disease using high-resolution mass spectrometry, serving healthcare providers, biopharmaceutical trial sponsors, and academic researchers globally.
Ownership category
akta.pro rank

C2N Diagnostics industry classification

Industry
Product category
Neurological Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Alzheimer's disease diagnostics
  • Blood-based biomarker testing
  • Mass spectrometry diagnostics
  • Neurodegenerative disease assays
  • Clinical laboratory services

Where C2N Diagnostics is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices3 records

Markets served

C2N Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Clinical Laboratory Testing Services: C2N performs its Precivity™ blood tests in its CAP-accredited, CLIA-certified, ISO 13485:2016 compliant laboratory in St. Louis, Missouri. Healthcare professionals order tests for patients, and results are returned to inform medical management and treatment decisions. Revenue is generated per test performed.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goPrecivityAD Test - $1,250 per test

Go-to-market motion1 record

Distribution channels10 records

Marketing channels6 records

C2N Diagnostics product offering

Product offering

Core offering

C2N Diagnostics develops and commercializes proprietary blood-based diagnostic tests for Alzheimer's disease and related neurodegenerative conditions using high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology. The core Precivity™ product line includes PrecivityAD®, PrecivityAD2™, and Precivity-ApoE™ clinical diagnostic tests, complemented by research-use-only tau assays (C2N eMTBR-tau243 and C2N %p-tau MAA) and bioanalytical services for pharmaceutical clinical trials. All clinical tests are processed in the company's CAP-accredited, CLIA-certified laboratory in St. Louis, Missouri, with global distribution through laboratory network and regional distribution partners.

Product overview

C2N Diagnostics offers a portfolio of blood-based diagnostic tests for Alzheimer's disease using proprietary high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies. The core clinical products include PrecivityAD2™ (for patients 50+), PrecivityAD® (for patients 55+), and Precivity-ApoE™. Research-use-only offerings include C2N eMTBR-tau243 plasma assay and C2N %p-tau MAA for tau pathology analysis. The company also provides bioanalytical services for clinical trials and pharmaceutical research partnerships. Tests are performed in the company's CAP-accredited, CLIA-certified, ISO 13485:2016 compliant facility in St. Louis, MO, and distributed globally through laboratory and distribution partnerships.

Differentiator

Problem solved

Functional benefit

Brands

  • PrecivityAD: Blood test for Alzheimer's disease intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia undergoing evaluation for Alzheimer's disease or dementia
  • PrecivityAD2
  • Precivity-ApoE

Products and services

  • PrecivityAD2™ Blood Test Blood test intended for patients aged 50 and older with signs or symptoms of mild cognitive impairment or dementia undergoing evaluation of Alzheimer's disease or dementia. Uses high-resolution mass spectrometry to detect amyloid plaques in the brain by measuring plasma p-tau217 and Aβ42/Aβ40 ratio. Performed in C2N's CAP-accredited, CLIA-certified laboratory.
  • PrecivityAD® Blood Test Original blood test intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia undergoing evaluation of Alzheimer's disease or dementia. Uses mass spectrometry to measure amyloid proteins and apolipoprotein E genetic risk factors for Alzheimer's disease.
  • Precivity-ApoE™ Blood Test Blood test indicated for adult patients for whom knowledge of apolipoprotein E2, E3, and E4 allele status may be informative for medical management and treatment decisions. Available through healthcare professional orders.
  • C2N eMTBR-tau243 Plasma Assay Research Use Only plasma assay that selectively detects a specific region of tau (endogenous Microtubule Binding Region) shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer's disease. Used for disease staging, predicting progression, and monitoring treatment efficacy in research and clinical trial settings.
  • C2N %p-tau MAA (Multi-Analyte Assay) Research Use Only p-tau multi-analyte assay using high-resolution mass spectrometry to precisely quantitate six analytes related to phosphorylated and non-phosphorylated tau forms (%p-tau181, %p-tau205, %p-tau217). Uses ratio of phosphorylated tau divided by non-phosphorylated tau to mitigate confounding factors such as age and medical comorbidities.
  • C2N eMTBR-tau243 (CSF) Assay Cerebrospinal fluid (CSF) assay launched by C2N for detecting eMTBR-tau243 biomarkers, selectively identifying tau fragment regions for Alzheimer's research applications.
  • Bioanalytical Services High-resolution mass spectrometry-based biomarker services for clinical trials, supporting pharmaceutical and biotechnology companies in maximizing quality and efficiency of neurodegeneration treatment trials. Assays have been used in over 200 Alzheimer's disease research studies globally.

Quantifiable outcome

  • 91% accuracy, 90% sensitivity, 92% specificity versus amyloid PET imaging
  • +4 more outcomes

Companies that use C2N Diagnostics

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

C2N Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

C2N Diagnostics partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered major, minor and core.

  • SouthGeneticsmajorChannel Partner/ Reseller/ Distributor · 1 June 2026Partnership to enable broader access to Precivity® blood tests across Latin America and Caribbean including Argentina, Chile, Colombia, Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela.
  • Codex GeneticsminorChannel Partner/ Reseller/ Distributor · 20 March 2026Partnership to launch PrecivityAD2 blood test in Hong Kong for early detection of Alzheimer's disease. Codex handles local regulatory compliance, distribution, and patient access.
  • BeauBrain HealthcaremajorChannel Partner/ Reseller/ Distributor · 11 March 2026Partnership to launch PrecivityAD2 blood test in South Korea, making the test accessible to healthcare professionals for detecting amyloid plaques in patients 50 and older with cognitive impairment.
  • Archerfish Precision DiagnosticsminorChannel Partner/ Reseller/ Distributor · 8 August 2025Distribution partner for PrecivityAD2 test in Singapore and Southeast Asian markets.
  • Dr. Dangs LabminorChannel Partner/ Reseller/ Distributor · 8 August 2025Distribution partner for PrecivityAD2 test in India.
  • Medical LinkminorChannel Partner/ Reseller/ Distributor · 8 August 2025Distribution partner for PrecivityAD2 test in Israel.
  • Milenia LabsminorChannel Partner/ Reseller/ Distributor · 8 August 2025Distribution partner for PrecivityAD2 test in Costa Rica and Mexico.
  • Accuserv Diagnostic CenterminorChannel Partner/ Reseller/ Distributor · 8 August 2025Distribution partner for PrecivityAD2 test in Philippines.
  • Grupo FleuryminorChannel Partner/ Reseller/ Distributor · 8 August 2025International laboratory partner for C2N's Precivity™ diagnostic tests.
  • HealiusminorChannel Partner/ Reseller/ Distributor · 8 August 2025International laboratory partner for C2N's Precivity™ diagnostic tests.
  • MedifordminorChannel Partner/ Reseller/ Distributor · 8 August 2025Research collaboration partner for Precivity™ Alzheimer's blood test expansion in Japan.
  • Splash ClinicalminorStrategic or Co-development Partner · 26 March 2025Partnership to transform global clinical trial recruitment for Alzheimer's disease using Precivity™ blood tests to identify eligible patients for clinical trials.
  • The Michael J. Fox FoundationcoreStrategic or Co-development Partner · 15 January 2025Research partnership to uncover new links between Parkinson's disease, Lewy Body Dementia, and Alzheimer's disease using C2N's biomarker tests.
  • UnilabsmajorChannel Partner/ Reseller/ Distributor · 7 August 2024Global partnership to make Precivity™ blood tests available across Unilabs' laboratory network in 75+ countries, advancing brain health diagnostics internationally.
  • Mayo Clinic LaboratoriesmajorChannel Partner/ Reseller/ Distributor · 27 June 2024C2N's Precivity™ tests offered through Mayo Clinic Laboratories, providing access through one of the most respected laboratory networks in the United States.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

C2N Diagnostics competitors and assessment

Company assessment

Direct peers

  • Quanterix: Quanterix operates a single-molecule array (Simoa) ultra-sensitive protein detection platform used by researchers and clinical labs for blood-based biomarkers, including neurodegenerative disease assays. Directly comparable to C2N in that it sells biomarker testing services and immunoassay-based kits to pharma and academic researchers pursuing early AD detection and other neurology applications.
  • ALZpath: ALZpath developed a proprietary p-tau217 antibody and offers a blood-based Alzheimer's diagnostic test as a laboratory-developed test. Directly competes with C2N's PrecivityAD2 by offering an alternative blood-based AD biomarker assay to the same healthcare provider and biopharma customer base.
  • Fujirebio (H.U. Group Holdings): Fujirebio developed the Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio assay, the first FDA-cleared blood test for AD assessment. Directly competes with C2N in clinical blood-based AD diagnostics, with established IVD manufacturing scale and global distribution.

Broad incumbents

  • Roche Diagnostics: Roche has launched Elecsys pTau217 blood-based AD assays as part of its broad diagnostics portfolio. While not specialized in neurology, Roche's massive installed base of immunoassay analyzers in hospital labs represents a significant competitive threat to specialty labs like C2N.
  • Eli Lilly: Lilly is commercializing Kisunla (donanemab) for early symptomatic AD and is investing in companion diagnostics and blood-based biomarkers. As a vertically integrated pharma developing its own diagnostic strategy, Lilly is both a potential partner and a competitor for C2N's clinical trial and patient testing services.
  • Sysmex: Sysmex developed an automated immunoassay platform for blood-based p-tau217 measurement (HISCL) and is expanding into clinical AD diagnostics in Japan and globally. Comparable to C2N as a blood-based AD test developer, with broader IVD scale but limited single-disease specialization.
  • Eisai: Eisai is a strategic investor and partner in C2N ($15M partnership) and commercializes Leqembi (lecanemab) for early AD. As both a commercial partner and developer of companion diagnostics, Eisai is highly comparable to C2N's positioning in the AD ecosystem, with broader pharma scale.
  • Biogen: Biogen developed Aduhelm and is a major AD therapeutics player with extensive investment in biomarker development. Operates in the same AD clinical ecosystem as C2N and is a potential pharma partner or acquirer for AD diagnostic capabilities.
  • AbbVie: AbbVie partnered with C2N on the C2N-8E12 (ABBV-8E12) Phase 1 program for Progressive Supranuclear Palsy. As a large neuroscience-focused pharma with AD/PSP programs, AbbVie is both a current partner and a comparable player in neurodegenerative biomarker-driven drug development.

Emerging players

  • SomaLogic: SomaLogic operates a SomaScan proteomics platform enabling large-scale biomarker discovery across multiple disease areas including neurodegeneration. Comparable to C2N in its use of advanced proteomic technology for biomarker discovery, though C2N is more clinically focused while SomaLogic serves primarily research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

C2N Diagnostics social profiles

Digital presence

C2N Diagnostics compliance and trust

Trust signal

Compliance7 records

C2N Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

C2N Diagnostics leadership team

Management profile

Number of profiles

Profiles4 records

C2N Diagnostics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

C2N Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C2N Diagnostics

What does C2N Diagnostics do?

C2N Diagnostics develops and commercializes proprietary blood-based diagnostic tests for Alzheimer's disease and related neurodegenerative conditions using high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology. The core Precivity™ product line includes PrecivityAD®, PrecivityAD2™, and Precivity-ApoE™ clinical diagnostic tests, complemented by research-use-only tau assays (C2N eMTBR-tau243 and C2N %p-tau MAA) and bioanalytical services for pharmaceutical clinical trials. All clinical tests are processed in the company's CAP-accredited, CLIA-certified laboratory in St. Louis, Missouri, with global distribution through laboratory network and regional distribution partners.

Is C2N Diagnostics a public or private company?

C2N Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was C2N Diagnostics founded?

C2N Diagnostics was founded in 2007. It employs 101 to 250 people.

Where is C2N Diagnostics based?

C2N Diagnostics is headquartered in St Louis, United States, in the North America region.

How does C2N Diagnostics make money?

One revenue line is on record: clinical Laboratory Testing Services.

Who are C2N Diagnostics's main competitors?

Direct peers on record are Quanterix, ALZpath and Fujirebio (H.U. Group Holdings). Broad incumbents are Roche Diagnostics, Eli Lilly, Sysmex, Eisai, Biogen and AbbVie. SomaLogic is listed as an emerging player.

Does C2N Diagnostics have an API?

No public API is recorded for C2N Diagnostics.

What industry is C2N Diagnostics in?

C2N Diagnostics's product category is Neurological Diagnostics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyC2N Diagnostics, LSI Medience partner to bring PrecivityAD2 to JapanC2N Diagnostics and LSI Medience announced a strategic partnership to pursue regulatory approval and commercialization of the PrecivityAD2 Alzheimer's blood test in Japan. The partnership follows recent U.S. FDA clearance of the test.Malaysia Latest NewsFDA Clears New Alzheimer’s Blood Tests for Symptomatic Adults as Young as 40The FDA cleared C2N Diagnostics' PrecivityAD2 and Roche's Elecsys pTau217 blood tests for assessing Alzheimer's-related brain changes in symptomatic adults. PrecivityAD2 showed 97.6% positive predictive value and 93.1% negative predictive value against amyloid PET or CSF biomarkers. The tests are not diagnostic and require clinical interpretation.Longevity.TechnologyUK’s Alzheimer’s diagnosis gap gets a new fixC2N Diagnostics, Cambridge Cognition, and The Alzheimer's Trust announced a partnership to integrate a blood test, cognitive app, and national infrastructure to cut UK Alzheimer's diagnosis waits. The average wait is 3.5 years, and the partnership aims to coordinate testing via The Alzheimer's Trust's network. The companies argue earlier diagnosis enables newer amyloid-targeting treatments.Longevity.TechnologyC2N Diagnostics expands UK partnership to improve Alzheimer’s diagnosisC2N Diagnostics announced a UK partnership with Cambridge Cognition and The Alzheimer's Trust to create an integrated diagnostic pathway for Alzheimer's disease. The pathway combines C2N's PrecivityAD2 blood test with CANTAB digital assessments and The Alzheimer's Trust's phlebotomy and MRI infrastructure. The company claims the combined approach detects Alzheimer's with about 90% accuracy versus 70% for typical GPs.Investing.comC2N Diagnostics partners with Cambridge Cognition in UK By Investing.comC2N Diagnostics and Cambridge Cognition announced a partnership with The Alzheimer's Trust to provide integrated Alzheimer's diagnostic services in the UK. The collaboration combines C2N's PrecivityAD2 blood test, Cambridge Cognition's CANTAB Pathway, and The Alzheimer's Trust's phlebotomy and MRI infrastructure. The test received UK regulatory approval in 2025 and FDA clearance.TradingViewRCS - Cambridge Cognition - Partnership with C2N and The Alzheimer's TrustC2N Diagnostics, Cambridge Cognition, and The Alzheimer's Trust announced a partnership on World Alzheimer's Day to improve Alzheimer's diagnosis in the UK. The collaboration integrates C2N's PrecivityAD2 blood test, Cambridge Cognition's CANTAB Pathway cognitive assessment, and The Alzheimer's Trust's phlebotomy and MRI infrastructure. The partnership aims to accelerate patient diagnosis and care pathways throughout the UK.InvestegatePartnership with C2N and The Alzheimer's TrustC2N Diagnostics, Cambridge Cognition, and The Alzheimer's Trust announced a partnership on World Alzheimer's Day to integrate the PrecivityAD2 blood test and CANTAB Pathway cognitive assessment for Alzheimer's diagnosis in the UK. The collaboration aims to address the UK's dementia crisis, where patients wait an average of 3.5 years for diagnosis. The partnership seeks to accelerate earlier and more accurate diagnosis through combined testing.Longevity.TechnologyFDA clears C2N Diagnostics’ first blood test for early Alzheimer’sThe FDA cleared C2N Diagnostics' PrecivityAD2 blood test for detecting amyloid plaques in symptomatic adults 40 and older. The test correctly predicted amyloid pathology 97.6% of the time and ruled it out 93.1% of the time in a validation study. The clearance is expected to reach clinics later this year.NewsweekNew Blood Test for Alzheimer’s Gets FDA Clearance—Here’s How It WorksThe FDA cleared C2N Diagnostics' PrecivityAD2 blood test for diagnosing Alzheimer's in adults 40 and older with cognitive symptoms. The test uses mass spectrometry to measure amyloid and tau proteins, achieving 97.6% positive and 93.1% negative predictive value. It is expected to be available later this year.Patient Care OnlineFDA Clears First-of-Its-Kind Alzheimer Blood Test for Adults With Cognitive SymptomsThe FDA cleared C2N Diagnostics' PrecivityAD2 blood test for adults aged 40+ with cognitive symptoms, the first such test. The test uses mass spectrometry to measure amyloid and tau ratios, with a positive predictive value of 97.6% and negative of 93.1% in a study of 1,142 participants. It is intended for clinical evaluation, not screening, and will be available later this year.